A round of Series B fundraising brought in $7.5 million for Ocugen. The firm plans to use the funds to support development of its clinical and preclinical pipeline of treatments for inflammatory, degenerative and neovascular sight-threatening diseases. The company has an ongoing clinical trial of OCU300 for ocular graft-versus-host disease and the preclinical-stage OCU100, developed as a treatment for degenerative eye diseases, including geographic atrophy and retinitis pigmentosa.
Fundraising round generates $7.5M for Ocugen
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.